Determinants of Drug Resistant Tuberculosis Among Tuberculosis Patients on Treatment in Gedeo Zone Public Healthcare Facilities, Southern Ethiopia, 2025. Unmatched case‒control study.

Determinants of Drug Resistant Tuberculosis Among Tuberculosis Patients on Treatment in Gedeo Zone Public Healthcare Facilities, Southern Ethiopia, 2025. Unmatched case‒control study. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Determinants of Drug Resistant Tuberculosis Among Tuberculosis Patients on Treatment in Gedeo Zone Public Healthcare Facilities, Southern Ethiopia, 2025. Unmatched case‒control study. Mebrat Mengesha, Alemayehu Tadesse, Taye Gari, Alemselam Zebdewos This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8915478/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Introduction: Drug-resistant tuberculosis (DR-TB) is a form of tuberculosis caused by Mycobacterium tuberculosis strains that do not respond to standard anti-TB drugs. Ethiopia ranked among the top 30 countries burdened by DR-TB in the world. Although drug-resistant tuberculosis is a growing public health concern in the Gedeo Zone, determinants of DR-TB are still inadequately explored, as few studies have been undertaken in this area. Therefore, this study aimed to assess the determinants of drug-resistant tuberculosis among TB patients receivingtreatment. Objectives : To assess the determinants of drug-resistant tuberculosis among TB patients receiving treatment in Gedeo Zone public healthcare facilities, southern Ethiopia, 2025 Methods : An institution-based unmatched case‒control study was conducted from July 21--August 19, 2025, with a total of 177 participants (59 cases and 118 controls) who attended public healthcare facilities in the Gedeo zone. A simple random sampling technique was used to select a study participant. The data were collected with the Kobo Toolbox and then exported to SPSS version 27 for analysis. Associations between dependent and independent variables were assessed via binary logistic regression. At the 95% CI, in bivariable analysis, a p value of <0.25 was used to select candidate variables for multivariable analysis. In the multivariable analysis, a p value of less than 0.05 was considered statistically significant. Result: In this study, 177 participants (59 cases and 118 controls) were enrolled, resulting in a 100% response rate. This study revealed that five factors were significantly associated with DR-TB in this study area: lack of formal education (AOR = 3.37, 95% CI: 1.09–10.42), urban residence (AOR = 2.54, 95% CI: 1.07–6.03), previous TB treatment history (AOR = 3.34, 95% CI: 1.57–7.09), counselling on DR-TB (AOR = 0.28, 95% CI: 0.10–0.78), and social stigma (AOR = 3.27, 95% CI: 1.56–6.84). Conclusion: Lack of formal education, urban residence, previous TB treatment history, counselling and social stigma was found to be determinants of DR-TB. Effective DR-TB control interventions focused on the above determinants need to be implemented. Infectious Diseases Drug resistance Tuberculosis Healthcare facility Gedeo Zone INTRODUCTION According to the World Health Organization, tuberculosis (TB) is a communicable infectious disease caused by the bacterium Mycobacterium tuberculosis that primarily affects the lungs but can, in some cases, extend its impact to other organs throughout the body ( 1 ). Drug-resistant tuberculosis (DR-TB) is a severe bacterial infectious disease caused by strains of Mycobacterium tuberculosis that are nonresponsive to one or more antimicrobial medications intended to treat tuberculosis ( 1 ). Drug-resistant tuberculosis encompasses several forms, including multidrug-resistant tuberculosis (MDR-TB), which is characterized by resistance to at least two of the most potent first-line antituberculotic drugs, isoniazid (INH) and rifampicin (RIF), and rifampicin-resistant tuberculosis (RR-TB), which is characterized by resistance to rifampicin (RIF), which may or may not present with resistance to other antituberculotic drugs, and extensively drug-resistant tuberculosis (XDR-TB), representing a more severe form of drug resistance characterized by resistance to isoniazid (INH) and rifampicin (RIF) and at least one fluoroquinolone, such as moxifloxacin or levofloxacin, and at least one second-line injectable antituberculotic drug, such as amikacin, kanamycin, or capreomycin ( 2 ). The development of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains of the disease, which are highly resistant to first- and second-line antituberculotic drugs, has made the global TB crisis even more critical, as standard treatment protocols are no longer effective and the challenge of managing and controlling this deadly infectious disease becomes even more difficult (3; 4). Tuberculosis, particularly drug-resistant tuberculosis, disproportionately burdens already fragile health systems in Africa, widens health inequalities, and erodes public health gains, most severely in southern Africa, due to high HIV prevalence, limited health care resources, and widespread socioeconomic challenges ( 5 ). Southern Ethiopia, like other regions of the country, experiences a significant burden of TB and, as such, a high DR-TB prevalence. The rates in this particular region, which are likely higher than the national average, place an extra burden on the already fragile health infrastructure ( 6 ). The WHO has set a target to reduce tuberculosis (TB) by 50 percent by the end of 2025, but thus far, only a small 8–3 percent reduction has been achieved, and the deadline is approaching ( 7 ). This lack of progress is largely due to the growing prevalence of drug-resistant tuberculosis (DR-TB), which makes effective treatment and control strategies very challenging ( 2 ). Although DR-TB prevention and treatment programs are in place according to national guidelines and recommendations of previous studies ( 8 ), the number of new cases continues to increase, which indicates that currently available evidence is insufficient to control the disease and that context-specific research is urgently needed. In this study area, therefore, locally relevant, evidence-based information is critical to guide effective interventions and reduce the burden of DR-TB in this area. Although drug-resistant tuberculosis is an increasing public health problem in the Gedeo Zone, determinants of DR-TB remain inadequately explored, as only a few studies have been conducted in this area thus far ( 6 ). Those previous studies identified several determinants of DR-TB, such as social stigma, living in a household with one or two rooms, having a previous history of TB treatment, having a baseline body mass index (BMI) less than 18.5 kg/m2, and having pulmonary TB or DM ( 8 ). However, the continuing increase in DR-TB cases suggests that additional social, environmental, and clinical factors may also play a role. Additionally, important regional perspectives are provided by a prior study ( 6 ) that included the Dilla University Referral Hospitals (DURH) TIC center as one of four study areas in southern Ethiopia; however, further context-specific investigations focused on the Gedeo Zone are warranted for a deeper understanding of the local determinants of drug-resistant tuberculosis. The existing evidence gap emphasizes how urgently more research in this area is needed to fully comprehend the complex and context-specific factors that lead to drug-resistant tuberculosis. The current lack of deep understanding makes designing an effective control strategy difficult. Generating up-to-date and locally relevant evidence is therefore essential to identify more determinants of DR-TB, guide focused interventions and strengthen ongoing efforts to reduce the burden of DR-TB in this area. Therefore, this study was aimed to assess the determinants of drug-resistant tuberculosis among TB patients receiving treatment in Gedeo Zone public healthcare facilities, southern Ethiopia. METHODS AND MATERIALS Study area and period This study was conducted in healthcare facilities in the Gedeo Zone, which is located in southern Ethiopia and is approximately 360 km south of Addis Ababa. The zone has 45 public health facilities distributed across 13 districts and serves a population of 1,330,796 people, according to the woreda-based plan of the 2017 Ethiopian fiscal year (EFY). Drug-resistant tuberculosis (DR-TB) is diagnosed at Dilla University Referral Hospital (DURH), which functions as a treatment initiation center (TIC). Treatment is started at DURH, and once a patient’s sputum test becomes negative, they are linked to their local health center for close follow-up. According to the Gedeo Zone Health Department's report, 3,380 drug-susceptible TB patients and 65 drug-resistant TB (DR-TB) patients currently receive treatment across various health facilities in the Gedeo Zone ( 9 ). The study was conducted from July 21–August 19, 2025. Study design An institution-based unmatched case‒control study was employed. Source and study population The source population of the study included all new and previously treated TB patients registered for treatment in Gedeo Zone healthcare facilities with documented drug susceptibility testing (DST). With respect to the study population, all randomly selected DR-TB patients currently receiving treatment at Gedeo Zone healthcare facilities were cases, whereas all randomly selected drug-susceptible TB patients receiving treatment at Gedeo Zone health facilities were controls. Eligibility criteria For cases, all confirmed DR-TB patients currently receiving treatment were included, and for controls, all confirmed drug-susceptible TB patients after 2 months of treatment were included in the study. For cases, patients with previous treatment for DR-TB were excluded, and For controls, patients in the intensive phase of treatment for drug-susceptible TB and patients with previous treatment for DR-TB were excluded from the study. Sampling size determination : To determine the proportion among cases and controls, the sample size was computed via the double population proportion formula by considering a ratio of cases to controls of 1:2, a power of 80, a 95% confidence interval, and an adjusted odds ratio of 0.26, with a proportion among cases of 0.743 and among controls of 0.429 from a study of drug-resistant tuberculosis patients in southern Ethiopia ( 7 ). For determinants of drug-resistant tuberculosis among tuberculosis patients receiving treatment, the sample size was computed via Epi Info version 7.2.5.0 software by considering a ratio of case to control of 1:2, a power of 80, a 95% confidence interval, and an odds ratio varying according to the variable. The sample size formula for the method described in Fleiss w/CC was used. When the adequacy of the sample size is considered, the largest sample size is 161. By adding a 10% nonresponse rate, the total sample size for this study was 177. Therefore, the total sample sizes for this study were 59 cases and 118 controls. Sampling procedure First, the list of all DR-TB patients diagnosed over 24 months as well as health care facilities where DR-TB patients were linked after being declared sputum negative was taken from the DURH TIC center. The sample was then proportionally allocated to all healthcare facilities on the basis of the number of DR-TB cases linked to them. One-third of the proportionally allocated sample was the number of cases needed from that facility, while 2/3rd of that was the control needed from the same facility. Finally, a simple random sampling technique was employed to select study participants on the basis of their serial number in the TB registration book until an allocated sample was obtained for each healthcare facility. When the allocated sample was equal to the number of cases on follow-up at that facility, all of it was included in the study. Variable of the study Dependent variable Drug resistant Tuberculosis Independent variable Sociodemographic and economic factors (i.e., age, sex, residence area, educational status, occupational status, monthly income). Behavioral factors (i.e., smoking, chat chewing, alcohol consumption, treatment interruption, social stigma, information about DR-TB, counselling on DR-TB, delay in seeking care). Environmental and household factors (i.e., number of rooms, crowding, contact with DR-TB patients, opening window habits, and distance of healthcare facilities from living areas). Clinical and comorbid factors (i.e., HIV status, nutritional status, hospitalization, previous treatment for TB, treatment failure, relapse). Operational definition: MDR-TB : Resistant to at least both isoniazid and rifampin on the basis of drug susceptibility testing ( 1 ). XDR-TB : DR-TB that fulfils the definition of MDR and is also resistant to any fluoroquinolone and at least one additional injectable anti-TB agent on the basis of drug susceptibility testing ( 1 ). HR : Resistant to isoniazid only RR : Resistant to rifampicin only DR-TB : Any one of the four categories of DR-TBs listed above. Patient : A patient with a confirmed diagnosis of MDR-TB or XDR-TB. Control : Drug-susceptible TB patients or TB patients declared to be drug susceptible by laboratory confirmation after 2 months of initial treatment. New patients : Patients who have never been treated for TB or have taken anti-TB drugs for less than one month ( 1 ). History of contact with DR-TB patients : Sharing living, learning or working space with smear-positive pulmonary DR-TB patients for 1 or more nights or extended during the 3 months prior to the current diagnosis ( 6 ). History of drug interruption : History of missing even a single dose of anti-TB therapy ( 10 ). Comorbid illness : Concurrently diagnosed conditions in TB patients, including under nutrition, HIV, diabetes mellitus and lung diseases (COPD, asthma) ( 6 ). Alcohol consumption : Currently, alcohol consumption is defined as drinking alcohol at least once a month ( 11 ). Smokers : Smokers who currently smoke or have smoked one or more cigarettes per day within the 12 months of TB diagnosis ( 11 ). Stigma : This is considered present if the patient reports experiencing isolation, discrimination, or reduced social support due to a current or past TB infection ( 6 ). Undernutrition : Age-specific WHO anthropometric tools were used to classify the nutritional status of patients as normal, mild, moderate or severe undernutrition, overweight or obese ( 12 ). Hospitalization : Documented or reported admission to the hospital for at least 2 days in the last 3 months before TB diagnosis ( 13 ). Distance from the nearest treatment center : classified as ‘near’ if the one-way walking time is less than 1 hour and ‘far’ if it takes 1 hour or more ( 14 ). The monthly income : low ( 3000) ( 15 ). Data collection tool and procedures A structured interview questionnaire was developed {Look at supplementary file} from the literature to gather data on sociodemographic and economic factors, environmental and household factors, behavioral factors, and clinical and comorbid factors was used to collect data. Using checklists, clinically and comorbidity-related data were collected from the client's chart. At each healthcare facility, data were collected by two nurse professionals via the Kobo toolbox in two isolated chronic Tb clinic units. Data quality management Before data collection, the structured questionnaire prepared for data collection was pretested in 5% of the study sample at Yirgalem Hospital, which is found in Sidama Regional State, Ethiopia. After the pre-test, the data collection questionnaire was carefully designed, translated and retranslated. The questionnaires were developed in English, translated to Amharic, and then returned to English to maintain consistency by a well-trained language expert. Two training sessions concerning the objective of the study, the study instruments, the consent form, how to interview, and the data collection procedure were given to the recruited data collectors. The data collection procedure was supervised closely. Supervision was made on a daily basis to check completeness and consistency. Prompt clarifications were given whenever ambiguity occurred during data collection. The collected data were rechecked for completeness by the principal investigator. Data processing and analysis After the data were collected via the Kobo toolbox, they were exported into SPSS software version 27 for analysis. Frequency distribution tables were used to describe some variables. A Hosmer‒Lemeshow goodness-of-fit test was used to assess multicollinearity, and it was found that the variance inflation factor (VIF) was 2, which suggested that the model's predictions were well calibrated and that the model fit the data well. Bivariable and multivariable logistic regression were employed to test the associations between the dependent and independent variables. In the bivariable analysis, a P value of < 0.25 was used to select candidate variables for multivariable analysis. In multivariable analysis, a P value of less than 0.05 was used to determine the statistical significance of the association, and an adjusted odds ratio (AOR) with a 95% confidence interval was used to determine the presence, strength, and direction of association between covariates and the outcome variable. RESULTS Sociodemographic characteristics of the respondents This study included a total of 177 participants, which included 59 drug-resistant TB patients (cases) and 118 drug-susceptible TB patients (controls), making a response rate of 100%. The majority of participants in both groups were 25 years of age or older, with male accounting for 40 (67.8%) of case, and 65 (55.1%) of the control group. The study participants ranged in age from 10–49 years, with a median age of 30 years (IQR ± 19.5). The most common occupation was farming overall, and there was a clear disparity in educational attainment, with 13 (22.8%) of the cases and 44 (77.2%) of the controls lacking any formal education. There was also variation in place of residence, with 63 (53%) of the controls living in rural areas and 37 (62%) of the cases living in rural areas. Similarly, the majority 34 (57.6%) of participants from cases and 73 (61.9%) from controls were married. Finally, over half of the cases 33 (55.9%) and more than one-third of the controls 43 (36.4%) reported earning less than 1500 ETB, indicating economic disparity (Table 1 ). Table 1 Sociodemographic characteristics of TB patients receiving treatment during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n = 177). Variable Category Case (%) Control (%) Sex Female 19 (32.2) 53 (44.9) Male 40 (67.8) 65 (55.1) Age Below 15 years 7 (53.8) 6 (46.2) 15–24 years 21 (40.4) 31 (59.6) 25 and older 31 (27.7) 81 (72.3) Occupation Farmer 15 (25.4) 29 (24.6) Housewife 11 (18.6) 27 (22.9) Table 1 (Continued) Merchant 9 (15.3) 34 (28.8) Other 24 (40.7) 28 (28.7) Educational status No formal education 13 (22.8) 44 (77.2) Primary 28 (37.8) 46 (62.2) Secondary and above 18 (39.1) 28 (60.9) Marital status Single 22 (37.3) 28 (23.7) Married 34 (57.6) 73 (61.9) Divorced 3 (5.1) 13 (11.0) Widowed 0 (0.0) 4 (3.4) Religion Protestant 47 (79.7%) 75 (63.6%) Orthodox 11 (18.6%) 30 (25.4%) Muslim 1 (1.7%) 11 (9.3%) Catholic 0 (0.0%) 2 (1.7%) Residence Rural 37 (62.7) 63 (53.4) Urban 22 (37.3) 55 (46.6) Monthly income in ETB Below 1500 33 (55.9) 43 (36.4) 1500–3000 12 (20.3) 19 (16.1) Above 3000 14 (23.7) 56 (47.5) ETB: Ethiopian Birr Behavioural and social characteristics of the study participants In this study, the majority of 54 (91.5%) of the case, and 106 (89.8%) of the control did not have a history of smoking, while alcohol consumption varied, with controls using alcohol more frequently 37 (31.4^) than did cases 12 (20.3%). Similarly, only 21 (17.8%) of the controls and 4 (6.8%) of the cases reported having a history of chat chewing. With respect to awareness, more than half 33 (55.9%) of the cases and 64 (54.2%) of the controls) of both groups did not hear about DR-TB. However, the majority of the respondents 53 (89.8%) of the cases and 85 (72.6%) of the controls did not receive counselling about DR-TB. Regarding social factors, 20 (33.9%) of the cases and 74 (62.7%) of the controls reported experiencing social stigma (Table 2 ). Table 2 Behavioral and social characteristics of the study participants during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n = 177). Variable Category Case (%) Control (%) History of smoking No 54 (91.5) 106 (89.8) Yes 5 (8.5) 12 (10.2) History of alcohol drinking. No 47 (79.7) 81 (68.6) Yes 12 (20.3) 37 (31.4) History of chewing chat No 55 (93.2) 97 (82.2) Yes 4 (6.8) 21 (17.8) Ever heard about DR-TB No 33 (55.9) 64 (54.2) Yes 26 (44.1) 54 (45.8) Ever got counselling about DR-TB No 53 (89.8) 85 (72.6) Yes 6 (10.2) 32 (27.4) Social stigma No 39 (66.1) 44 (37.3) Yes 20 (33.9) 74 (62.7) History of drug interruptions No 43 (72.9) 95 (80.5) Yes 16 (27.1) 23 (19.5) Reason for drug interruption Forget to take 3 (18.8) 12 (52.2) Side effect 1 (6.3) 2 (8.7) Symptoms resolved 12 (75.0) 9 (39.1) DR-TB: Drug-resistant tuberculosis Environmental characteristics of the study participants Regarding family size, over half of the cases 29 (50.9%) had only one to two family members, whereas 29 (26.6%) of the controls did. The majority of the controls 81 (71.7%) resided in homes with two or more rooms, whereas 33 (55.9%) of the cases did. Almost all cases 55 (93.2%) and controls 97 (84.3%) had in a house which has windows. 49 (83.1%) of the cases and 36 (30.5%) of the controls did not have a history of contact with DR-TB patients, and 34 (28.8%) of the controls were not sure of their contact status. Finally, the case group was relatively closer to healthcare facilities, with 50 (84.7%) of the cases were living within one hour of a healthcare facility, compared with 75 (63.6%) of the controls (Table 3 ). Table 3 Environmental characteristics of the study participants during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n = 177). Variable Category Case (%) Control (%) Number of family members 1–2 people 29 (50.9) 29 (26.6) 3–4 people 16 (28.1) 46 (42.2) 5–6 people 11 (19.3) 28 (25.7) 7 and more 1 (1.8) 6 (5.5) Number of room in living home Only one 26 (44.1) 32 (28.3) Two or more 33 (55.9) 81 (71.7) Presence of windows in rooms No 4 (6.8) 18 (15.7) Yes 55 (93.2) 97 (84.3) Habit of opening windows No 20 (36.4) 34 (35.1) Yes 35 (63.6) 63 (64.9) History of contact with DR-TB patient I don’t know 1 (1.7) 34 (28.8) No 49 (83.1) 36 (30.5) Yes 9 (15.3) 48 (40.7) Distance of healthcare facility from living area Less than 1 hour 50 (84.7) 75 (63.6) More than 1 hour 9 (15.3) 43 (36.4) DR-TB: Drug-resistant tuberculosis Clinical characteristics and comorbidities of the study participants Among the cases, rifampicin-resistant TB (RR-TB) was the most prevalent form of drug-resistant TB, accounting for 42 (71.2%) of the cases. A considerable proportion 18 (30.5%) of the cases and 66 (55.9%) of the controls had a history of previous TB treatment. Relapsed cases accounted for 18 (30.5%) of the cases and 13 (11.0%) of the controls. The majority 51 (86.4%) of cases and 96 (81.4%) of the controls had negative HIV serostatus, and in both groups, the majority of participants did not report having diabetes mellitus, cardiovascular disease, or chronic lung disease concurrently. There was a noticeable difference in nutritional status between the cases and the controls. 94 (79.6%) of the controls maintained a normal nutritional status, whereas only 28 (47.5%) of the patients were found to have a normal nutritional status (Table 4 ). Table 4 Clinical characteristics and comorbidity condition of the study participants during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n = 177). Variable Category Case (%) Control (%) Types of Drug-Resistant TB cases HR-TB 4 (6.8) 0 (0.0) MDR-TB 13 (22.0) 0 (0.0) RR-TB 42 (71.2) 0 (0.0) History of previous TB treatment No 41 (69.5) 52 (44.1) Yes 18 (30.5) 66 (55.9) History of hospitalization No 45 (76.3) 87 (73.7) Yes 14 (23.7) 31 (26.3) Category of the patient New 33 (55.9) 91 (77.1) Relapse 18 (30.5) 13 (11.0) Return after default 8 (13.6) 14 (11.9) HIV sero-status of the patient Negative 51 (86.4) 96 (81.4) Positive 8 (13.6) 13 (11.0) Unknown 0 (0.0) 9 (7.6) Have concomitant DM No 56 (94.9) 107 (91.5) Yes 3 (5.1) 10 (8.5) Cardiovascular diseases (HTN, HF, Stroke) No 56 (94.9) 107 (91.5) Yes 3 (5.1) 10 (8.5) Concomitant lung diseases (Asthma, COPD, other) No 58 (98.3) 114 (96.6) Yes 1 (1.7) 4 (3.4) Table 4 (Continued) Nutritional status (Based on age appropriate anthropometry) Normal 28 (47.5) 94 (79.6) Mild undernutrition 15 (25.4) 16 (13.6) Moderate undernutrition 11 (18.6) 5 (4.2) Severe undernutrition 5 (8.5) 3 (2.5) COPD: Chronic Obstructive Pulmonary Disease; DM: Diabetes Mellitus; DR-TB: Drug-resistant tuberculosis; HF: Heart Failure; HIV: Human Immunodeficiency Virus; HTN: Hypertension Determinants of drug-resistant tuberculosis : The associations of each independent variable with the outcome variable were assessed separately via binary logistic regression, and variables with p < 0.25, such as age, educational status, area of residence, history of alcohol consumption, previous TB treatment, history of anti-TB drug interruption, DR-TB counselling, and social stigma, were considered candidates for the final model. After all the assumptions of logistic regression were confirmed to be fulfilled, all the variables with p < 0.25 in the bivariate analysis were tested in the final model. Then, variables with a significance level of p < 0.05 were considered significant determinants of DR-TB. After adjusting for other covariates, five variables, educational status, area of residence, previous TB treatment, DR-TB counselling, and social stigma, were found to be significantly associated with DR-TB in this study area. Accordingly, the odds of developing DR-TB were 3.37 times greater for participants without formal education than for those with secondary education or higher (AOR = 3.370; 95% CI: 1.09, 10.416). Similarly, living in an urban area was also linked to higher odds; the odds of DR-TB were 2.54 times higher for urban dwellers than for rural dwellers (AOR = 2.535; 95% CI: 1.067, 6.025). One important protective factor was receiving counselling regarding DR-TB; those who received counselling had a 72% lower chance of contracting DR-TB than those who did not (AOR = 0.281; 95% CI: 0.102, 0.777). Moreover, those who had previously received TB treatment had 3.34 times greater odds of developing DR-TB (AOR = 3.340; 95% CI: 1.574, 7.087). Finally, the likelihood of developing DR-TB was considerably increased by social stigma (AOR = 3.268; 95% CI: 1.562, 6.835) (Table 5 ). Table 5 Bivariate and multivariate analyses were performed during the study of determinants of drug-resistant tuberculosis in Gedeo Zone healthcare facilities, 2025 (n = 177). Variable Case (%) Control (%) COR (95% CI) AOR (95% CI) Age in year Below 15 years 7 (53.8) 6 (46.2) 1 1 15–24 years 21 (40.4) 31 (59.6) 1.77 (0.886, 3.534) 1.483 (0.605, 0.632) 25 and above 31 (27.7) 81 (72.3) 0.58(0.171, 1.973) 0.432 (0.093, 2.003) Educational status Secondary and above 18 (39.1) 28 (60.9) 1 1 Primary 28 (37.8) 46 (62.2) 1.056 (0.496, 2.249) 1.973 (0.747, 5.210) No formal education 13 (22.8) 44 (77.2) 2.176 (0.924, 5.123) 3.370 (1.09, 10.416)* Residence area Rural 37 (62.7) 63 (53.4) 1 1 Urban 22 (37.3) 55 (46.6) 1.468 (0.774–2.784) 2.535 (1.067, 6.025)* History of drinking alcohol No 47 (79.7) 81 (68.6) 1 1 Yes 12 (20.3) 37 (31.4) 1.789 (0.850–3.764) 1.634 (0.610, 4.375) Ever got counselling about DR-TB No 53 (89.8) 85 (72.6) 1 1 Yes 6 (10.2) 32 (27.4) 0.301 (0.118–0.767) 0.281 (0.102, 0.777)* History of previous TB treatment No 41 (69.5) 52 (44.1) 1 1 Yes 18 (30.5) 66 (55.9) 2.891 (1.490–5.609) 3.340(1.574, 7.087)* Table 5 (Continued) History of drug interruptions No 43 (72.9) 95 (80.5) 1 1 Yes 16 (27.1) 23 (19.5) 0.651 (0.313–1.354) 0.556 (0.235, 1.315) Social stigma No 39 (66.1) 44 (37.3) 1 1 Yes 20 (33.9) 74 (62.7) 0.305 (0.158–0.587) 3.268 (1.562, 6.835)* AOR: adjusted odds ratio; COR: crude odds ratio; DR-TB: drug-resistant tuberculosis; TB: tuberculosis*; a significant variable with a p value < 0.05 DISCUSSION This study assessed determinants of drug-resistant tuberculosis among patients receiving treatment in Gedeo Zone health facilities in southern Ethiopia. Five factors, namely, educational status, urban residency, counselling on DR-TB, previous TB treatment, and social stigma, were found to be statistically significant determinants of DR-TB. These results demonstrate that the occurrence of DR-TB is multifactorial and influenced by a combination of behavioral, environmental, sociodemographic, and clinical factors rather than being attributed to a single cause. This study revealed that educational status is a significant determinant of drug-resistant tuberculosis (DR-TB). Individuals with no formal education had 3.37 times greater odds of developing DR-TB than those with at least a secondary education. This finding is consistent with a number of prior studies that reported that a lack of formal education was a significant risk factor for DR-TB (7; 16). According to those studies, the risk of developing DR-TB was 2.2–4.4 times higher for those without formal education than for their counterparts. The consistency of findings across studies may be accounted for by the role of education in health literacy, awareness, and treatment adherence. The importance of early health-seeking behavior, appropriate medication use, and ongoing adherence to long-term TB treatment regimens are more likely to be understood by those with higher levels of education, whereas those with lower levels of education may struggle to understand health information, which could result in delayed diagnosis, inappropriate medication use, and a greater risk of drug resistance. Furthermore, socioeconomic position and education are strongly correlated. People with higher levels of education typically have better employment, incomes, and living conditions, which makes it easier for them to obtain high-quality healthcare. Each of these factors can lower the chance of contracting tuberculosis and the development of drug-resistant strains. Urban residents were 2.54 times more likely to have DR-TB than rural residents were in this study area. This finding contrasts with several studies that reported that rural residents are 2.54–3 times more likely to develop DR-TB than urban residents are (17; 18; 19). This discrepancy is likely due to differences in healthcare access, environmental conditions, and demographic characteristics. As illustrated by several studies and reports, the Gedeo Zone has a high population density, and the urban area of the zone has an even higher population density (20; 21), which could account for this discrepancy. Higher population densities can facilitate the transmission of DR-TB due to the crowded living conditions and frequent social interactions that are characteristic of urban settings. Despite the fact that people residing in rural areas have less access to healthcare, rural areas may have lower transmission rates because of their less crowded populations and less social interaction. The diagnostic and reporting rates of medical conditions are also better in urban areas, which could explain the greater number of DR-TB patients in urban regions than in rural regions. In this study, counselling about DR-TB was identified as a strong protective factor, with a 72% lower odd of DR-TB in participants who received counselling from healthcare providers than in those who did not. This finding is consistent with the finding that patients who did not receive counselling had a fivefold greater risk of developing DR-TB (22; 23). This consistency of findings may reflect the fact that counselling educates patients on the need for adherence to their drug regimen and treatment interruption, which reduces the risk of resistance, while building patient-provider trust and psychological support, which also play important roles in effective treatment. In general, the consistency of findings reinforces the necessity for appropriate counselling as part of tuberculosis control. This study also revealed that previous TB treatment was a significant risk factor for DR-TB, which was 3.34 times greater than the risk for people who did not have a history of previous TB treatment. Previous TB treatment has been identified as one of the best predictors of DR-TB in several other studies, and in some studies, the risk is even greater (up to 11.8 times greater) (24; 25; 26). It is scientifically plausible that lung cavities and fibrotic tissue, which are commonly found in patients after TB episodes, serve as reservoirs of Mycobacterium, as anti-TB drugs poorly penetrate these areas, allowing bacilli to survive and evolve, encouraging the development of mutations that are resistant to these drugs. Strengthening the follow-up of previously treated patients is essential to prevent both the emergence of new resistant strains and the spread of existing strains. This study also demonstrated that social stigma was a significant predictor of drug-resistant tuberculosis (DR-TB). The participants who experienced stigma had 3.27 times higher odds of developing DR-TB than did those who did not. This finding is in line with other studies in other settings that identified stigma as one of the most significant predictors of DR-TB, with adjusted odds ratios ranging from 5.1–8.9 (11; 27). These similarities among studies demonstrate that stigma is a critical component of the epidemiology of DR-TB because it often leads to nonadherence to treatment, hiding of illness, and delays in seeking care, all of which contribute to the emergence and transmission of resistant forms of the disease. Social stigma can lead patients to delay or avoid seeking care, stop their drugs, or hide their illness, all of which facilitate the emergence and spread of resistant forms of the disease. Thus, control of TB and DR-TB will require more than just improvements in diagnostic and treatment regimens; efforts must include community education, patient empowerment, and a reduction in discrimination to increase adherence to treatment and reduce the burden of drug resistance. Strength and Limitations of the study Controls after intensive phase of treatment were included to avoid potential misclassifications. Data collectors from other healthcare facilities were used to reduce social desirability and interviewer’s bias. Cases and controls were selected from the same facilities to enhance comparability, generalizability and minimize selection bias. All facilities providing DR-TB follow-up service were included in the study which enhances representativeness of the sample. One of the study's weaknesses could be attributed to its limited sample size. This limitation may be reflected in the large confidence intervals for factors that showed relationships and those that did not. A large sample size, which requires more resources, might be necessary for an exact assessment. Furthermore, because the data were collected at a health facility, participants may have given information in support of hospital staff out of frustration, which could have resulted in social desirability bias. As data was based on participants report, recall bias may have affected the result. Due to retrospective nature of case-control study, temporal relationship of exposure and outcome cannot clearly be ascertained. Some confounding could have been introduced due to unmatched nature of this study. CONCLUSSION This study identified multiple significant factors contributing to the development of drug-resistant tuberculosis (DR-TB), including social stigma, previous TB treatment, lack of formal education, urban residence, and insufficient counselling, emphasizing the necessity of integrated multidimensional interventions that combine counselling, psychosocial support, and community engagement, which are essential for enhancing treatment adherence and reducing stigma. Furthermore, close monitoring of patients with a history of TB treatment and targeted interventions in urban settings are critical to effectively address drug-resistant tuberculosis (DR-TB). Addressing these challenges requires multifaceted interventions. Efforts should focus on launching sustained, multiplatform public health campaigns (using local radio, community meetings, and religious institutions) that emphasize that TB is a curable disease and not a moral failure or a curse. Testimonials from successfully treated patients can be used to humanize the condition. Moreover, engaging respected community and religious leaders as "TB champions" to speak openly about TB, counter misinformation, and encourage community support for affected individuals and families is essential to create awareness in the community to prevent disease transmission from individuals to individuals. The implementation of enhanced adherence support for all first-time TB patients through directly observed therapy (DOT) short course, ideally by a trained family member or community health worker, will help patients who are not susceptible to MDR-TB. The goal is to ensure a 100% cure rate for new cases to prevent the emergence of resistance. Finally, implementing a standardized, simple counselling checklist for all patients and their treatment supporters is an essential asset in preventing the disease. Key messages should be repeated, and understanding should be verified through "teach-back" methods (where the patient explains the information in their own words) to enhance their knowledge about the nature of the disease. Abbreviations AOR Adjusted Odds Ratio CI Confidence Interval COPD Chronic Obstructive Pulmonary Disease COR Crude Odds Ratio DM Diabetes Mellitus DR-TB Drug Resistant Tuberculosis DURH Dilla University Referral Hospital ETB Ethiopian Birr HF Heart Failure HIV Human Immunodeficiency Virus HR-TB Isoniazid Resistant TB HTN Hypertension MDR-TB Multidrug Resistant Tuberculosis RR Relative Risk RR-TB Rifampicin resistant tuberculosis TIC Treatment Initiation Center WHO World Health Organization XR-TB Extensive Drug Resistant Tuberculosis Declarations Ethical approval and consent to participate All procedures used in this study adhered to the ethical principles of the Declaration of Helsinki for medical research with human beings. The ethical review committee of Hawassa University's College of Medicine and Health Science provided approval for this study. An official letter was given to the MDR-TB Diagnostic Centre at Dilla University College of Medicine and Health Science. Written informed consent was obtained from all the participants and from the legal guardians of the participants who were illiterate and minors. The information collected from the respondents had never been used for purposes other than this study. The confidentiality and privacy of the information were ensured. Clinical trial Number Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Conflict of interest The authors declare that there are no conflicts of interest among the authors or between the authors and institutions. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-from-profit sectors. Author contributions Mebrat Mengesha, Alemselam Zebdewos, Taye Gari and Alemayehu Tadesse all contributed significantly and equally to the work reported, whether in the study design, execution, acquisition of data, analysis, and interpretation, or in all of these areas; they also participated in the article's drafting, revision, and critical review; endorsed the final version for publication; and decided which journal to submit it to. Acknowledgements The authors are grateful to the Advisors, data collectors and study participants, whose efforts and contributions made this study possible. Data availability The datasets generated and/or analysed during the current study are not publicly available [as it is the word of the participants, it may contain the privacy of an individual or maintain the privacy and confidentiality of the participants but are available from the corresponding author upon reasonable request. References WHO. WHO consolidated guidelines on tuberculosis (2022) Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, update WHO (2024) Global tuberculosis report 2024. Geneva Bagcchi S (2023) WHO's Global Tuberculosis Report 2022. Lancet Microbe 4(1):e20 Sidek MY, Kamarul Zaman MF, Nik Rosmawati NH, Zamzurina AB (2024) Drug-resistant tuberculosis in Malaysia: Prevalence, characteristics, and treatment outcomes. Med J Malay 79(6):661–668 Ismail N, Ismail F, Omar SV, Blows L, Gardee Y, Koornhof H et al (2018) Drug resistant tuberculosis in Africa: Current status, gaps and opportunities. Afr J Lab Med 7(2):781 Abdulkerim BMS, Mathewos A et al (2022) Determinants of Multidrug-Resistant Mycobacterium tuberculosis Infection: A Multicenter Study from Southern Ethiopia. Infect Drug Resist 2022:15 3523–3535 Biru D, Woldesemayat EM (2020) Determinants of Drug-Resistant Tuberculosis in Southern Ethiopia: A Case-Control Study. Infect drug Resist 13:1823–1829 Hatiya M, Merid Y, Mola A, Belayneh F, Ali MM (2025) Prevalence of drug-resistant Mycobacterium tuberculosis and its associated factors among tuberculosis patients attending Dilla university referral hospital, Ethiopia. BMC Infect Dis 25(1):797 Wolde Z, Tadesse T, Tadesse T, Biru A, Abebe W (2020) Land size and landlessness as connotations for food security in rural low-income farmers: A case of Gedeo Zone, Southern Ethiopia. J Agricultural Sci Pract 5(1):36–45 Mesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D, Amare M et al (2018) Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLoS ONE 13(6):e Sileshi MLD, Solomon B (2021) Determinants of multi drug resistant tuberculosis among tuberculosis patients in southwest Ethiopia: Unmatched case control study (FANTA) (2016) FaNTAIP. Nutrition Assessment, Counseling, and Support (NACS): A User’s Guide—Module 2: Nutrition Assessment and Classification, Version 2. FHI 360/FANTA, Washington, DC Chen G, Xu K, Sun F, Sun Y, Kong Z, Fang B (2020) Risk Factors of Multidrug-Resistant Bacteria in Lower Respiratory Tract Infections: A Systematic Review and Meta-Analysis. 2020:7268519 Wako WG, Wasie A, Wayessa Z, Fikrie A (2021) Determinants of health system diagnostic delay of pulmonary tuberculosis in Gurage and Siltie zones, South Ethiopia: a cross-sectional study. BMJ open. ;11(10) Meresa D, Berhe G, Tadesse K, Gebru M, Gebrezgabiher G (2025) Assessing the determinants of drug-resistant tuberculosis in selected hospitals in Tigray region, Northern Ethiopia: a case-control study. J Health Popul Nutr 44(1):267 Fikre ATT, Shaweno T (2019) Determinants of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients in Southern Ethiopia: A Case Control Study. J Med Bacterio 8(1, 2):1–12 Zereabruk K, Kahsay TTH et al (2024) Determinants of multidrugresistant tuberculosis among adults undergoing treatment for tuberculosis in Tigray Region, Ethiopia: a case-control study. BMJ Open Respir Res Goel S, Thakur D, Singh A (2021) Determinants of drug resistant & drug sensitive tuberculosis patients from North India-a case control study. Indian J Tuberc 68S:S108–S14 Oumer N, Atnafu DD, Worku GT, Tsehay AK (2021) Determinants of Multi-drug resistant Tuberculosis in four treatment centers of Eastern Amhara, Ethiopia: A case-control study. J Infect developing Ctries 15(5):687–695 Muluneh AA, Kassa ZY, Siyoum M, Gebretsadik A, Woldeyes Y, Tenaw Z (2020) Determinants of Sub-Optimal Birth Spacing in Gedeo Zone, South Ethiopia: A Case–Control Study. Int J Women's Health 12(null):549–556 Kodama Y (2007) New role of cooperatives in Ethiopia: the case of Ethiopian coffee farmers cooperatives. Afr Study Monogr. ;35 Franke MA, Emmrich JV, Ranjaharinony F, Ravololohanitra OG, Andriamasy HE, Knauss S et al (2024) A cross-sectional analysis of the effectiveness of a nutritional support programme for people with tuberculosis in Southern Madagascar. 13(1):13 Nyamagoud SB, Dsouza PD, Chitralu SPP, Solankure K, Swamy AHV (2025) Impact of patient counseling on medication adherence and drug resistance patterns in tuberculosis patients kalu TY, Clements ACA, Xu Z, Bai L, Alene KA (2024) Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study. BMC Infect Dis 24(1):198 Tsige KEG (2020) Risk factors for multi Drug_Resistant Tuberculosis among newly diagnosed MDR-TB patients of all Africa leprosy, Tuberculosis and rehabilitation training center. Alert) Hospitals, Addis Ababa, Ethiopia Ying X, Wei Z, Ruijuan Q, Junhong (2022) Tang. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS ONE Demelash A, Berhanu S (2020) Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia. Infect Drug Resist 2017:10 209–213 Additional Declarations The authors declare no competing interests. Supplementary Files EnglishversionquestionaireorInterviewguide.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8915478","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":593775704,"identity":"65d57503-7cb0-4e76-92ea-bea714dbaf6e","order_by":0,"name":"Mebrat Mengesha","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA50lEQVRIiWNgGAWjYFACHiCukODhZ2A+AGRJyBCp5YyNjGQDWwJICw9xWhjb0mwMGngMYCbgB7rtvcc+fGA7zGMgdubzqxs1FjwM7IePbsCnxezMueSZM3gO85hL526zzjkGdBhPWtoNvFpu5Bgz80gc5rGcnbvNOIcNqEWCxwy/lvtvjJn/GAAddjvnmXHOP2K03OAxZmZISANpYX6c20aMljN5yYw9B2x4JGenmTHn9knwsBH0y/Gzhxl+/pOw55dOfvw551udHD/74WN4tSADNgkwSaxyEGD+QIrqUTAKRsEoGDkAAKV5Rd+GJDQ5AAAAAElFTkSuQmCC","orcid":"","institution":"School of Public Health, College of Health Sciences and Medicine, Hawassa University, Hawassa, Ethiopia","correspondingAuthor":true,"prefix":"","firstName":"Mebrat","middleName":"","lastName":"Mengesha","suffix":""},{"id":593775705,"identity":"a6eb556c-4ce5-49b0-b8fc-e67fa773bab2","order_by":1,"name":"Alemayehu Tadesse","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDUlEQVRIiWNgGAWjYDACdgiVwMBwIP0DQwWQyczcgF8LM0wL44FnDAfOgEQYidXCfPAZw8E2EJuAFv5m5qMbfrbZ5BkcO5z2+OO82mj+dqCWHxXbcGqROMyWdrO3La3Y4MyxdIOD247nzjjM2MDYc+Y2bmsO85jd4G07nLjhxpkEiYPbjuU2ALUwM7bh1iJ/mP/bzb9t/xM33H//QeLgnGO58wlpMTjMw3abt+1A4oYDB9IkDjbU5G4gpMXwMJvZbZlzyYkzDxxIBvrnQO5GoJaD+Pwid7z52c03ZXaJfQcOJD6oqKnLnXf+8MEHPyrweB8EGNkQoQEmD+BXDwJ/4Kw6wopHwSgYBaNgxAEAiVZt4Vti/UAAAAAASUVORK5CYII=","orcid":"","institution":"Institute of Health, Bule Hora University, Hagere Mariam, Ethiopia.","correspondingAuthor":true,"prefix":"","firstName":"Alemayehu","middleName":"","lastName":"Tadesse","suffix":""},{"id":593775706,"identity":"260e12dc-5896-459c-b249-76f153854cca","order_by":2,"name":"Taye Gari","email":"","orcid":"","institution":"School of Public Health, College of Health Sciences and Medicine, Hawassa University, Hawassa, Ethiopia","correspondingAuthor":false,"prefix":"","firstName":"Taye","middleName":"","lastName":"Gari","suffix":""},{"id":593775707,"identity":"c1f9f5a0-b65a-49c8-bec8-52878a56fde6","order_by":3,"name":"Alemselam Zebdewos","email":"","orcid":"","institution":"School of Public Health, College of Health Sciences and Medicine, Hawassa University, Hawassa, Ethiopia","correspondingAuthor":false,"prefix":"","firstName":"Alemselam","middleName":"","lastName":"Zebdewos","suffix":""}],"badges":[],"createdAt":"2026-02-19 08:34:56","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-8915478/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8915478/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":103050585,"identity":"aa9d39df-0828-4860-9b15-9e61f8d22547","added_by":"auto","created_at":"2026-02-20 07:50:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1458291,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8915478/v1/be1593c3-0ad1-484d-bca3-c4a5d909c190.pdf"},{"id":103034831,"identity":"21245385-563f-444e-9c86-a322b1bf0b8f","added_by":"auto","created_at":"2026-02-20 01:01:38","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":20623,"visible":true,"origin":"","legend":"","description":"","filename":"EnglishversionquestionaireorInterviewguide.docx","url":"https://assets-eu.researchsquare.com/files/rs-8915478/v1/f7eff8075553c346aa1c18b2.docx"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eDeterminants of Drug Resistant Tuberculosis Among Tuberculosis Patients on Treatment in Gedeo Zone Public Healthcare Facilities, Southern Ethiopia, 2025. Unmatched case‒control study.\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eAccording to the World Health Organization, tuberculosis (TB) is a communicable infectious disease caused by the bacterium \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e that primarily affects the lungs but can, in some cases, extend its impact to other organs throughout the body (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Drug-resistant tuberculosis (DR-TB) is a severe bacterial infectious disease caused by strains of \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e that are nonresponsive to one or more antimicrobial medications intended to treat tuberculosis (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Drug-resistant tuberculosis encompasses several forms, including multidrug-resistant tuberculosis (MDR-TB), which is characterized by resistance to at least two of the most potent first-line antituberculotic drugs, isoniazid (INH) and rifampicin (RIF), and rifampicin-resistant tuberculosis (RR-TB), which is characterized by resistance to rifampicin (RIF), which may or may not present with resistance to other antituberculotic drugs, and extensively drug-resistant tuberculosis (XDR-TB), representing a more severe form of drug resistance characterized by resistance to isoniazid (INH) and rifampicin (RIF) and at least one fluoroquinolone, such as moxifloxacin or levofloxacin, and at least one second-line injectable antituberculotic drug, such as amikacin, kanamycin, or capreomycin (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe development of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains of the disease, which are highly resistant to first- and second-line antituberculotic drugs, has made the global TB crisis even more critical, as standard treatment protocols are no longer effective and the challenge of managing and controlling this deadly infectious disease becomes even more difficult (3; 4). Tuberculosis, particularly drug-resistant tuberculosis, disproportionately burdens already fragile health systems in Africa, widens health inequalities, and erodes public health gains, most severely in southern Africa, due to high HIV prevalence, limited health care resources, and widespread socioeconomic challenges (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Southern Ethiopia, like other regions of the country, experiences a significant burden of TB and, as such, a high DR-TB prevalence. The rates in this particular region, which are likely higher than the national average, place an extra burden on the already fragile health infrastructure (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). The WHO has set a target to reduce tuberculosis (TB) by 50 percent by the end of 2025, but thus far, only a small 8\u0026ndash;3 percent reduction has been achieved, and the deadline is approaching (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). This lack of progress is largely due to the growing prevalence of drug-resistant tuberculosis (DR-TB), which makes effective treatment and control strategies very challenging (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). Although DR-TB prevention and treatment programs are in place according to national guidelines and recommendations of previous studies (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e), the number of new cases continues to increase, which indicates that currently available evidence is insufficient to control the disease and that context-specific research is urgently needed. In this study area, therefore, locally relevant, evidence-based information is critical to guide effective interventions and reduce the burden of DR-TB in this area.\u003c/p\u003e \u003cp\u003eAlthough drug-resistant tuberculosis is an increasing public health problem in the Gedeo Zone, determinants of DR-TB remain inadequately explored, as only a few studies have been conducted in this area thus far (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). Those previous studies identified several determinants of DR-TB, such as social stigma, living in a household with one or two rooms, having a previous history of TB treatment, having a baseline body mass index (BMI) less than 18.5 kg/m2, and having pulmonary TB or DM (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). However, the continuing increase in DR-TB cases suggests that additional social, environmental, and clinical factors may also play a role. Additionally, important regional perspectives are provided by a prior study (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e) that included the Dilla University Referral Hospitals (DURH) TIC center as one of four study areas in southern Ethiopia; however, further context-specific investigations focused on the Gedeo Zone are warranted for a deeper understanding of the local determinants of drug-resistant tuberculosis. The existing evidence gap emphasizes how urgently more research in this area is needed to fully comprehend the complex and context-specific factors that lead to drug-resistant tuberculosis. The current lack of deep understanding makes designing an effective control strategy difficult. Generating up-to-date and locally relevant evidence is therefore essential to identify more determinants of DR-TB, guide focused interventions and strengthen ongoing efforts to reduce the burden of DR-TB in this area. Therefore, this study was aimed to assess the determinants of drug-resistant tuberculosis among TB patients receiving treatment in Gedeo Zone public healthcare facilities, southern Ethiopia.\u003c/p\u003e"},{"header":"METHODS AND MATERIALS","content":"\u003cp\u003e \u003cstrong\u003eStudy area and period\u003c/strong\u003e \u003cp\u003eThis study was conducted in healthcare facilities in the Gedeo Zone, which is located in southern Ethiopia and is approximately 360 km south of Addis Ababa. The zone has 45 public health facilities distributed across 13 districts and serves a population of 1,330,796 people, according to the woreda-based plan of the 2017 Ethiopian fiscal year (EFY). Drug-resistant tuberculosis (DR-TB) is diagnosed at Dilla University Referral Hospital (DURH), which functions as a treatment initiation center (TIC). Treatment is started at DURH, and once a patient\u0026rsquo;s sputum test becomes negative, they are linked to their local health center for close follow-up. According to the Gedeo Zone Health Department's report, 3,380 drug-susceptible TB patients and 65 drug-resistant TB (DR-TB) patients currently receive treatment across various health facilities in the Gedeo Zone (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). The study was conducted from July 21\u0026ndash;August 19, 2025.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eStudy design\u003c/strong\u003e \u003cp\u003eAn institution-based unmatched case‒control study was employed.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eSource and study population\u003c/strong\u003e \u003cp\u003eThe source population of the study included all new and previously treated TB patients registered for treatment in Gedeo Zone healthcare facilities with documented drug susceptibility testing (DST). With respect to the study population, all randomly selected DR-TB patients currently receiving treatment at Gedeo Zone healthcare facilities were cases, whereas all randomly selected drug-susceptible TB patients receiving treatment at Gedeo Zone health facilities were controls.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eEligibility criteria\u003c/strong\u003e \u003cp\u003eFor cases, all confirmed DR-TB patients currently receiving treatment were included, and for controls, all confirmed drug-susceptible TB patients after 2 months of treatment were included in the study. For cases, patients with previous treatment for DR-TB were excluded, and For controls, patients in the intensive phase of treatment for drug-susceptible TB and patients with previous treatment for DR-TB were excluded from the study.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e\u003cb\u003eSampling size determination\u003c/b\u003e: To determine the proportion among cases and controls, the sample size was computed via the double population proportion formula by considering a ratio of cases to controls of 1:2, a power of 80, a 95% confidence interval, and an adjusted odds ratio of 0.26, with a proportion among cases of 0.743 and among controls of 0.429 from a study of drug-resistant tuberculosis patients in southern Ethiopia (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). For determinants of drug-resistant tuberculosis among tuberculosis patients receiving treatment, the sample size was computed via Epi Info version 7.2.5.0 software by considering a ratio of case to control of 1:2, a power of 80, a 95% confidence interval, and an odds ratio varying according to the variable. The sample size formula for the method described in Fleiss w/CC was used. When the adequacy of the sample size is considered, the largest sample size is 161. By adding a 10% nonresponse rate, the total sample size for this study was 177. Therefore, the total sample sizes for this study were \u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003e59\u003c/span\u003e cases and \u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003e118\u003c/span\u003e controls.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eSampling procedure\u003c/strong\u003e \u003cp\u003eFirst, the list of all DR-TB patients diagnosed over 24 months as well as health care facilities where DR-TB patients were linked after being declared sputum negative was taken from the DURH TIC center. The sample was then proportionally allocated to all healthcare facilities on the basis of the number of DR-TB cases linked to them. One-third of the proportionally allocated sample was the number of cases needed from that facility, while 2/3rd of that was the control needed from the same facility. Finally, a simple random sampling technique was employed to select study participants on the basis of their serial number in the TB registration book until an allocated sample was obtained for each healthcare facility. When the allocated sample was equal to the number of cases on follow-up at that facility, all of it was included in the study.\u003c/p\u003e \u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eVariable of the study\u003c/h2\u003e \u003cdiv id=\"Sec4\" class=\"Section3\"\u003e \u003ch2\u003eDependent variable\u003c/h2\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eDrug resistant Tuberculosis\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e\n\u003ch3\u003eIndependent variable\u003c/h3\u003e\n\u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eSociodemographic and economic factors\u003c/b\u003e (i.e., age, sex, residence area, educational status, occupational status, monthly income).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eBehavioral factors\u003c/b\u003e (i.e., smoking, chat chewing, alcohol consumption, treatment interruption, social stigma, information about DR-TB, counselling on DR-TB, delay in seeking care).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eEnvironmental and household factors\u003c/b\u003e (i.e., number of rooms, crowding, contact with DR-TB patients, opening window habits, and distance of healthcare facilities from living areas).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eClinical and comorbid factors\u003c/b\u003e (i.e., HIV status, nutritional status, hospitalization, previous treatment for TB, treatment failure, relapse).\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e\n\u003ch3\u003eOperational definition:\u003c/h3\u003e\n\u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eMDR-TB\u003c/b\u003e: Resistant to at least both isoniazid and rifampin on the basis of drug susceptibility testing (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eXDR-TB\u003c/b\u003e: DR-TB that fulfils the definition of MDR and is also resistant to any fluoroquinolone and at least one additional injectable anti-TB agent on the basis of drug susceptibility testing (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eHR\u003c/b\u003e: Resistant to isoniazid only\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eRR\u003c/b\u003e: Resistant to rifampicin only\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eDR-TB\u003c/b\u003e: Any one of the four categories of DR-TBs listed above.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003ePatient\u003c/b\u003e: A patient with a confirmed diagnosis of MDR-TB or XDR-TB.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eControl\u003c/b\u003e: Drug-susceptible TB patients or TB patients declared to be drug susceptible by laboratory confirmation after 2 months of initial treatment.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eNew patients\u003c/b\u003e: Patients who have never been treated for TB or have taken anti-TB drugs for less than one month (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eHistory of contact with DR-TB patients\u003c/b\u003e: Sharing living, learning or working space with smear-positive pulmonary DR-TB patients for 1 or more nights or extended during the 3 months prior to the current diagnosis (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eHistory of drug interruption\u003c/b\u003e: History of missing even a single dose of anti-TB therapy (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eComorbid illness\u003c/b\u003e: Concurrently diagnosed conditions in TB patients, including under nutrition, HIV, diabetes mellitus and lung diseases (COPD, asthma) (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eAlcohol consumption\u003c/b\u003e: Currently, alcohol consumption is defined as drinking alcohol at least once a month (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eSmokers\u003c/b\u003e: Smokers who currently smoke or have smoked one or more cigarettes per day within the 12 months of TB diagnosis (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eStigma\u003c/b\u003e: This is considered present if the patient reports experiencing isolation, discrimination, or reduced social support due to a current or past TB infection (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eUndernutrition\u003c/b\u003e: Age-specific WHO anthropometric tools were used to classify the nutritional status of patients as normal, mild, moderate or severe undernutrition, overweight or obese (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eHospitalization\u003c/b\u003e: Documented or reported admission to the hospital for at least 2 days in the last 3 months before TB diagnosis (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eDistance from the nearest treatment center\u003c/b\u003e: classified as \u0026lsquo;near\u0026rsquo; if the one-way walking time is less than 1 hour and \u0026lsquo;far\u0026rsquo; if it takes 1 hour or more (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eThe monthly income\u003c/b\u003e: low (\u0026lt;\u0026thinsp;1500 ETB), moderate (1500\u0026ndash;3000) or high (\u0026gt;\u0026thinsp;3000) (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eData collection tool and procedures\u003c/strong\u003e \u003cp\u003eA structured interview questionnaire was developed {Look at supplementary file} from the literature to gather data on sociodemographic and economic factors, environmental and household factors, behavioral factors, and clinical and comorbid factors was used to collect data. Using checklists, clinically and comorbidity-related data were collected from the client's chart. At each healthcare facility, data were collected by two nurse professionals via the Kobo toolbox in two isolated chronic Tb clinic units.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eData quality management\u003c/strong\u003e \u003cp\u003eBefore data collection, the structured questionnaire prepared for data collection was pretested in 5% of the study sample at Yirgalem Hospital, which is found in Sidama Regional State, Ethiopia. After the pre-test, the data collection questionnaire was carefully designed, translated and retranslated. The questionnaires were developed in English, translated to Amharic, and then returned to English to maintain consistency by a well-trained language expert. Two training sessions concerning the objective of the study, the study instruments, the consent form, how to interview, and the data collection procedure were given to the recruited data collectors. The data collection procedure was supervised closely. Supervision was made on a daily basis to check completeness and consistency. Prompt clarifications were given whenever ambiguity occurred during data collection. The collected data were rechecked for completeness by the principal investigator.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eData processing and analysis\u003c/strong\u003e \u003cp\u003eAfter the data were collected via the Kobo toolbox, they were exported into SPSS software version 27 for analysis. Frequency distribution tables were used to describe some variables. A Hosmer‒Lemeshow goodness-of-fit test was used to assess multicollinearity, and it was found that the variance inflation factor (VIF) was 2, which suggested that the model's predictions were well calibrated and that the model fit the data well. Bivariable and multivariable logistic regression were employed to test the associations between the dependent and independent variables. In the bivariable analysis, a P value of \u0026lt;\u0026thinsp;0.25 was used to select candidate variables for multivariable analysis. In multivariable analysis, a P value of less than 0.05 was used to determine the statistical significance of the association, and an adjusted odds ratio (AOR) with a 95% confidence interval was used to determine the presence, strength, and direction of association between covariates and the outcome variable.\u003c/p\u003e \u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003e \u003cstrong\u003eSociodemographic characteristics of the respondents\u003c/strong\u003e \u003cp\u003eThis study included a total of 177 participants, which included 59 drug-resistant TB patients (cases) and 118 drug-susceptible TB patients (controls), making a response rate of 100%. The majority of participants in both groups were 25 years of age or older, with male accounting for 40 (67.8%) of case, and 65 (55.1%) of the control group. The study participants ranged in age from 10\u0026ndash;49 years, with a median age of 30 years (IQR\u0026thinsp;\u0026plusmn;\u0026thinsp;19.5). The most common occupation was farming overall, and there was a clear disparity in educational attainment, with 13 (22.8%) of the cases and 44 (77.2%) of the controls lacking any formal education. There was also variation in place of residence, with 63 (53%) of the controls living in rural areas and 37 (62%) of the cases living in rural areas. Similarly, the majority 34 (57.6%) of participants from cases and 73 (61.9%) from controls were married. Finally, over half of the cases 33 (55.9%) and more than one-third of the controls 43 (36.4%) reported earning less than 1500 ETB, indicating economic disparity (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSociodemographic characteristics of TB patients receiving treatment during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n\u0026thinsp;=\u0026thinsp;177).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCategory\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCase (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eControl (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e19 (32.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e53 (44.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e40 (67.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e65 (55.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBelow 15 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7 (53.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e6 (46.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15\u0026ndash;24 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e21 (40.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e31 (59.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e25 and older\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e31 (27.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e81 (72.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eOccupation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFarmer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15 (25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e29 (24.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11 (18.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e27 (22.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003e(Continued)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMerchant\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (15.3)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e34 (28.8)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOther\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24 (40.7)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e28 (28.7)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eEducational status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo formal education\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e13 (22.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e44 (77.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e28 (37.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e46 (62.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSecondary and above\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e18 (39.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e28 (60.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eMarital status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSingle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e22 (37.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e28 (23.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMarried\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e34 (57.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e73 (61.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDivorced\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3 (5.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e13 (11.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWidowed\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e4 (3.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eReligion\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eProtestant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e47 (79.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e75 (63.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOrthodox\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11 (18.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e30 (25.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMuslim\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1 (1.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e11 (9.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCatholic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2 (1.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eResidence\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRural\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e37 (62.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e63 (53.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUrban\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e22 (37.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e55 (46.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMonthly income in ETB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBelow 1500\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e33 (55.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e43 (36.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1500\u0026ndash;3000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12 (20.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e19 (16.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbove 3000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e14 (23.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e56 (47.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003eETB: Ethiopian Birr\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eBehavioural and social characteristics of the study participants\u003c/strong\u003e \u003cp\u003eIn this study, the majority of 54 (91.5%) of the case, and 106 (89.8%) of the control did not have a history of smoking, while alcohol consumption varied, with controls using alcohol more frequently 37 (31.4^) than did cases 12 (20.3%). Similarly, only 21 (17.8%) of the controls and 4 (6.8%) of the cases reported having a history of chat chewing. With respect to awareness, more than half 33 (55.9%) of the cases and 64 (54.2%) of the controls) of both groups did not hear about DR-TB. However, the majority of the respondents 53 (89.8%) of the cases and 85 (72.6%) of the controls did not receive counselling about DR-TB. Regarding social factors, 20 (33.9%) of the cases and 74 (62.7%) of the controls reported experiencing social stigma (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBehavioral and social characteristics of the study participants during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n\u0026thinsp;=\u0026thinsp;177).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCategory\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCase (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eControl (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHistory of smoking\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e54 (91.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e106 (89.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5 (8.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12 (10.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHistory of alcohol drinking.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e47 (79.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e81 (68.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12 (20.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e37 (31.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHistory of chewing chat\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e55 (93.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e97 (82.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e21 (17.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eEver heard about DR-TB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e33 (55.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e64 (54.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e26 (44.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e54 (45.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eEver got counselling about DR-TB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e53 (89.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e85 (72.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6 (10.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e32 (27.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSocial stigma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e39 (66.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e44 (37.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e20 (33.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e74 (62.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHistory of drug interruptions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e43 (72.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e95 (80.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e16 (27.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e23 (19.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eReason for drug interruption\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eForget to take\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3 (18.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12 (52.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSide effect\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1 (6.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2 (8.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSymptoms resolved\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12 (75.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e9 (39.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003eDR-TB: Drug-resistant tuberculosis\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eEnvironmental characteristics of the study participants\u003c/strong\u003e \u003cp\u003eRegarding family size, over half of the cases 29 (50.9%) had only one to two family members, whereas 29 (26.6%) of the controls did. The majority of the controls 81 (71.7%) resided in homes with two or more rooms, whereas 33 (55.9%) of the cases did. Almost all cases 55 (93.2%) and controls 97 (84.3%) had in a house which has windows. 49 (83.1%) of the cases and 36 (30.5%) of the controls did not have a history of contact with DR-TB patients, and 34 (28.8%) of the controls were not sure of their contact status. Finally, the case group was relatively closer to healthcare facilities, with 50 (84.7%) of the cases were living within one hour of a healthcare facility, compared with 75 (63.6%) of the controls (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eEnvironmental characteristics of the study participants during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n\u0026thinsp;=\u0026thinsp;177).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCategory\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCase (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eControl (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eNumber of family members\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;2 people\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e29 (50.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e29 (26.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u0026ndash;4 people\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e16 (28.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e46 (42.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026ndash;6 people\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11 (19.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e28 (25.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 and more\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1 (1.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e6 (5.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eNumber of room in living home\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOnly one\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e26 (44.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e32 (28.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTwo or more\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e33 (55.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e81 (71.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003ePresence of windows in rooms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e18 (15.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e55 (93.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e97 (84.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHabit of opening windows\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e20 (36.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e34 (35.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e35 (63.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e63 (64.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eHistory of contact with DR-TB patient\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eI don\u0026rsquo;t know\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1 (1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e34 (28.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e49 (83.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e36 (30.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9 (15.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e48 (40.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eDistance of healthcare facility from living area\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLess than 1 hour\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50 (84.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e75 (63.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMore than 1 hour\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9 (15.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e43 (36.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003eDR-TB: Drug-resistant tuberculosis\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eClinical characteristics and comorbidities of the study participants\u003c/strong\u003e \u003cp\u003eAmong the cases, rifampicin-resistant TB (RR-TB) was the most prevalent form of drug-resistant TB, accounting for 42 (71.2%) of the cases. A considerable proportion 18 (30.5%) of the cases and 66 (55.9%) of the controls had a history of previous TB treatment. Relapsed cases accounted for 18 (30.5%) of the cases and 13 (11.0%) of the controls. The majority 51 (86.4%) of cases and 96 (81.4%) of the controls had negative HIV serostatus, and in both groups, the majority of participants did not report having diabetes mellitus, cardiovascular disease, or chronic lung disease concurrently. There was a noticeable difference in nutritional status between the cases and the controls. 94 (79.6%) of the controls maintained a normal nutritional status, whereas only 28 (47.5%) of the patients were found to have a normal nutritional status (Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eClinical characteristics and comorbidity condition of the study participants during the study of determinants of drug-resistant tuberculosis, Gedeo Zone healthcare facilities, 2025 (n\u0026thinsp;=\u0026thinsp;177).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCategory\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCase (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eControl (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eTypes of Drug-Resistant TB cases\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHR-TB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMDR-TB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e13 (22.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRR-TB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e42 (71.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHistory of previous TB treatment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e41 (69.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e52 (44.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e18 (30.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e66 (55.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHistory of hospitalization\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e45 (76.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e87 (73.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e14 (23.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e31 (26.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eCategory of the patient\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNew\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e33 (55.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e91 (77.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRelapse\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e18 (30.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e13 (11.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eReturn after default\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8 (13.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e14 (11.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eHIV sero-status of the patient\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNegative\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e51 (86.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e96 (81.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePositive\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8 (13.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e13 (11.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUnknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e9 (7.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHave concomitant DM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e56 (94.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e107 (91.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3 (5.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e10 (8.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eCardiovascular diseases (HTN, HF, Stroke)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e56 (94.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e107 (91.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3 (5.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e10 (8.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eConcomitant lung diseases (Asthma, COPD, other)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e58 (98.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e114 (96.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1 (1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e4 (3.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003e(Continued)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eNutritional status (Based on age appropriate anthropometry)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e28 (47.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e94 (79.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMild undernutrition\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15 (25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e16 (13.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eModerate undernutrition\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11 (18.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e5 (4.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSevere undernutrition\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5 (8.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3 (2.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003eCOPD: Chronic Obstructive Pulmonary Disease; DM: Diabetes Mellitus; DR-TB: Drug-resistant tuberculosis; HF: Heart Failure; HIV: Human Immunodeficiency Virus; HTN: Hypertension\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eDeterminants of drug-resistant tuberculosis\u003c/b\u003e: The associations of each independent variable with the outcome variable were assessed separately via binary logistic regression, and variables with p\u0026thinsp;\u0026lt;\u0026thinsp;0.25, such as age, educational status, area of residence, history of alcohol consumption, previous TB treatment, history of anti-TB drug interruption, DR-TB counselling, and social stigma, were considered candidates for the final model. After all the assumptions of logistic regression were confirmed to be fulfilled, all the variables with p\u0026thinsp;\u0026lt;\u0026thinsp;0.25 in the bivariate analysis were tested in the final model. Then, variables with a significance level of p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 were considered significant determinants of DR-TB. After adjusting for other covariates, five variables, educational status, area of residence, previous TB treatment, DR-TB counselling, and social stigma, were found to be significantly associated with DR-TB in this study area. Accordingly, the odds of developing DR-TB were 3.37 times greater for participants without formal education than for those with secondary education or higher (AOR\u0026thinsp;=\u0026thinsp;3.370; 95% CI: 1.09, 10.416). Similarly, living in an urban area was also linked to higher odds; the odds of DR-TB were 2.54 times higher for urban dwellers than for rural dwellers (AOR\u0026thinsp;=\u0026thinsp;2.535; 95% CI: 1.067, 6.025). One important protective factor was receiving counselling regarding DR-TB; those who received counselling had a 72% lower chance of contracting DR-TB than those who did not (AOR\u0026thinsp;=\u0026thinsp;0.281; 95% CI: 0.102, 0.777). Moreover, those who had previously received TB treatment had 3.34 times greater odds of developing DR-TB (AOR\u0026thinsp;=\u0026thinsp;3.340; 95% CI: 1.574, 7.087). Finally, the likelihood of developing DR-TB was considerably increased by social stigma (AOR\u0026thinsp;=\u0026thinsp;3.268; 95% CI: 1.562, 6.835) (Table\u0026nbsp;\u003cspan refid=\"Tab8\" class=\"InternalRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab7\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBivariate and multivariate analyses were performed during the study of determinants of drug-resistant tuberculosis in Gedeo Zone healthcare facilities, 2025 (n\u0026thinsp;=\u0026thinsp;177).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCase (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCOR (95% CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAOR (95% CI)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge in year\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBelow 15 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7 (53.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6 (46.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e15\u0026ndash;24 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e21 (40.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e31 (59.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.77 (0.886, 3.534)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.483 (0.605, 0.632)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e25 and above\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e31 (27.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e81 (72.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.58(0.171, 1.973)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.432 (0.093, 2.003)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEducational status\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSecondary and above\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e18 (39.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e28 (60.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e28 (37.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e46 (62.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.056 (0.496, 2.249)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.973 (0.747, 5.210)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo formal education\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13 (22.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e44 (77.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.176 (0.924, 5.123)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.370 (1.09, 10.416)*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eResidence area\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRural\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e37 (62.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e63 (53.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUrban\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e22 (37.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e55 (46.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.468 (0.774\u0026ndash;2.784)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e2.535 (1.067, 6.025)*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHistory of drinking alcohol\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e47 (79.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e81 (68.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12 (20.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e37 (31.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.789 (0.850\u0026ndash;3.764)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.634 (0.610, 4.375)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEver got counselling about DR-TB\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e53 (89.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e85 (72.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e6 (10.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e32 (27.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.301 (0.118\u0026ndash;0.767)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.281 (0.102, 0.777)*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHistory of previous TB treatment\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e41 (69.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e52 (44.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e18 (30.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e66 (55.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.891 (1.490\u0026ndash;5.609)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e3.340(1.574, 7.087)*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab8\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003e(Continued)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHistory of drug interruptions\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e43 (72.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e95 (80.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e16 (27.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e23 (19.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.651 (0.313\u0026ndash;1.354)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.556 (0.235, 1.315)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSocial stigma\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e39 (66.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e44 (37.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e20 (33.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e74 (62.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.305 (0.158\u0026ndash;0.587)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e3.268 (1.562, 6.835)*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eAOR: adjusted odds ratio; COR: crude odds ratio; DR-TB: drug-resistant tuberculosis; TB: tuberculosis*; a significant variable with a p value\u0026thinsp;\u0026lt;\u0026thinsp;0.05\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eThis study assessed determinants of drug-resistant tuberculosis among patients receiving treatment in Gedeo Zone health facilities in southern Ethiopia. Five factors, namely, educational status, urban residency, counselling on DR-TB, previous TB treatment, and social stigma, were found to be statistically significant determinants of DR-TB. These results demonstrate that the occurrence of DR-TB is multifactorial and influenced by a combination of behavioral, environmental, sociodemographic, and clinical factors rather than being attributed to a single cause.\u003c/p\u003e \u003cp\u003eThis study revealed that educational status is a significant determinant of drug-resistant tuberculosis (DR-TB). Individuals with no formal education had 3.37 times greater odds of developing DR-TB than those with at least a secondary education. This finding is consistent with a number of prior studies that reported that a lack of formal education was a significant risk factor for DR-TB (7; 16). According to those studies, the risk of developing DR-TB was 2.2\u0026ndash;4.4 times higher for those without formal education than for their counterparts. The consistency of findings across studies may be accounted for by the role of education in health literacy, awareness, and treatment adherence. The importance of early health-seeking behavior, appropriate medication use, and ongoing adherence to long-term TB treatment regimens are more likely to be understood by those with higher levels of education, whereas those with lower levels of education may struggle to understand health information, which could result in delayed diagnosis, inappropriate medication use, and a greater risk of drug resistance. Furthermore, socioeconomic position and education are strongly correlated. People with higher levels of education typically have better employment, incomes, and living conditions, which makes it easier for them to obtain high-quality healthcare. Each of these factors can lower the chance of contracting tuberculosis and the development of drug-resistant strains.\u003c/p\u003e \u003cp\u003eUrban residents were 2.54 times more likely to have DR-TB than rural residents were in this study area. This finding contrasts with several studies that reported that rural residents are 2.54\u0026ndash;3 times more likely to develop DR-TB than urban residents are (17; 18; 19). This discrepancy is likely due to differences in healthcare access, environmental conditions, and demographic characteristics. As illustrated by several studies and reports, the Gedeo Zone has a high population density, and the urban area of the zone has an even higher population density (20; 21), which could account for this discrepancy. Higher population densities can facilitate the transmission of DR-TB due to the crowded living conditions and frequent social interactions that are characteristic of urban settings. Despite the fact that people residing in rural areas have less access to healthcare, rural areas may have lower transmission rates because of their less crowded populations and less social interaction. The diagnostic and reporting rates of medical conditions are also better in urban areas, which could explain the greater number of DR-TB patients in urban regions than in rural regions. In this study, counselling about DR-TB was identified as a strong protective factor, with a 72% lower odd of DR-TB in participants who received counselling from healthcare providers than in those who did not. This finding is consistent with the finding that patients who did not receive counselling had a fivefold greater risk of developing DR-TB (22; 23). This consistency of findings may reflect the fact that counselling educates patients on the need for adherence to their drug regimen and treatment interruption, which reduces the risk of resistance, while building patient-provider trust and psychological support, which also play important roles in effective treatment. In general, the consistency of findings reinforces the necessity for appropriate counselling as part of tuberculosis control.\u003c/p\u003e \u003cp\u003eThis study also revealed that previous TB treatment was a significant risk factor for DR-TB, which was 3.34 times greater than the risk for people who did not have a history of previous TB treatment. Previous TB treatment has been identified as one of the best predictors of DR-TB in several other studies, and in some studies, the risk is even greater (up to 11.8 times greater) (24; 25; 26). It is scientifically plausible that lung cavities and fibrotic tissue, which are commonly found in patients after TB episodes, serve as reservoirs of Mycobacterium, as anti-TB drugs poorly penetrate these areas, allowing bacilli to survive and evolve, encouraging the development of mutations that are resistant to these drugs. Strengthening the follow-up of previously treated patients is essential to prevent both the emergence of new resistant strains and the spread of existing strains.\u003c/p\u003e \u003cp\u003eThis study also demonstrated that social stigma was a significant predictor of drug-resistant tuberculosis (DR-TB). The participants who experienced stigma had 3.27 times higher odds of developing DR-TB than did those who did not. This finding is in line with other studies in other settings that identified stigma as one of the most significant predictors of DR-TB, with adjusted odds ratios ranging from 5.1\u0026ndash;8.9 (11; 27). These similarities among studies demonstrate that stigma is a critical component of the epidemiology of DR-TB because it often leads to nonadherence to treatment, hiding of illness, and delays in seeking care, all of which contribute to the emergence and transmission of resistant forms of the disease. Social stigma can lead patients to delay or avoid seeking care, stop their drugs, or hide their illness, all of which facilitate the emergence and spread of resistant forms of the disease. Thus, control of TB and DR-TB will require more than just improvements in diagnostic and treatment regimens; efforts must include community education, patient empowerment, and a reduction in discrimination to increase adherence to treatment and reduce the burden of drug resistance.\u003c/p\u003e\n\u003ch3\u003eStrength and Limitations of the study\u003c/h3\u003e\n\u003cp\u003eControls after intensive phase of treatment were included to avoid potential misclassifications. Data collectors from other healthcare facilities were used to reduce social desirability and interviewer\u0026rsquo;s bias. Cases and controls were selected from the same facilities to enhance comparability, generalizability and minimize selection bias. All facilities providing DR-TB follow-up service were included in the study which enhances representativeness of the sample. One of the study's weaknesses could be attributed to its limited sample size. This limitation may be reflected in the large confidence intervals for factors that showed relationships and those that did not. A large sample size, which requires more resources, might be necessary for an exact assessment. Furthermore, because the data were collected at a health facility, participants may have given information in support of hospital staff out of frustration, which could have resulted in social desirability bias. As data was based on participants report, recall bias may have affected the result. Due to retrospective nature of case-control study, temporal relationship of exposure and outcome cannot clearly be ascertained. Some confounding could have been introduced due to unmatched nature of this study.\u003c/p\u003e"},{"header":"CONCLUSSION","content":"\u003cp\u003eThis study identified multiple significant factors contributing to the development of drug-resistant tuberculosis (DR-TB), including social stigma, previous TB treatment, lack of formal education, urban residence, and insufficient counselling, emphasizing the necessity of integrated multidimensional interventions that combine counselling, psychosocial support, and community engagement, which are essential for enhancing treatment adherence and reducing stigma. Furthermore, close monitoring of patients with a history of TB treatment and targeted interventions in urban settings are critical to effectively address drug-resistant tuberculosis (DR-TB). Addressing these challenges requires multifaceted interventions. Efforts should focus on launching sustained, multiplatform public health campaigns (using local radio, community meetings, and religious institutions) that emphasize that TB is a curable disease and not a moral failure or a curse. Testimonials from successfully treated patients can be used to humanize the condition. Moreover, engaging respected community and religious leaders as \"TB champions\" to speak openly about TB, counter misinformation, and encourage community support for affected individuals and families is essential to create awareness in the community to prevent disease transmission from individuals to individuals. The implementation of enhanced adherence support for all first-time TB patients through directly observed therapy (DOT) short course, ideally by a trained family member or community health worker, will help patients who are not susceptible to MDR-TB. The goal is to ensure a 100% cure rate for new cases to prevent the emergence of resistance. Finally, implementing a standardized, simple counselling checklist for all patients and their treatment supporters is an essential asset in preventing the disease. Key messages should be repeated, and understanding should be verified through \"teach-back\" methods (where the patient explains the information in their own words) to enhance their knowledge about the nature of the disease.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eAOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eAdjusted Odds Ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eCI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eConfidence Interval\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eCOPD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eChronic Obstructive Pulmonary Disease\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eCOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eCrude Odds Ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eDM\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eDiabetes Mellitus\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eDR-TB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eDrug Resistant Tuberculosis\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eDURH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eDilla University Referral Hospital\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eETB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eEthiopian Birr\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eHF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eHeart Failure\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eHIV\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eHuman Immunodeficiency Virus\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eHR-TB\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eIsoniazid Resistant TB\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eHTN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eMDR-TB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eMultidrug Resistant Tuberculosis\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eRR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eRelative Risk\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eRR-TB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eRifampicin resistant tuberculosis\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eTIC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eTreatment Initiation Center\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eWHO\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eWorld Health Organization\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 126px;\"\u003e\n \u003cp\u003eXR-TB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 498px;\"\u003e\n \u003cp\u003eExtensive Drug Resistant Tuberculosis\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e"},{"header":"Declarations","content":" \u003cp\u003e \u003cstrong\u003eEthical approval and consent to participate\u003c/strong\u003e \u003cp\u003e All procedures used in this study adhered to the ethical principles of the Declaration of Helsinki for medical research with human beings. The ethical review committee of Hawassa University's College of Medicine and Health Science provided approval for this study. An official letter was given to the MDR-TB Diagnostic Centre at Dilla University College of Medicine and Health Science. Written informed consent was obtained from all the participants and from the legal guardians of the participants who were illiterate and minors. The information collected from the respondents had never been used for purposes other than this study. The confidentiality and privacy of the information were ensured.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eClinical trial Number\u003c/h2\u003e \u003cp\u003eNot applicable.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eConsent for publication\u003c/h2\u003e \u003cp\u003eNot applicable.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCompeting interests\u003c/strong\u003e \u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eConflict of interest\u003c/strong\u003e \u003cp\u003eThe authors declare that there are no conflicts of interest among the authors or between the authors and institutions.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eThis research did not receive any specific grant from funding agencies in the public, commercial, or not-from-profit sectors.\u003c/p\u003e\u003ch2\u003eAuthor contributions\u003c/h2\u003e \u003cp\u003eMebrat Mengesha, Alemselam Zebdewos, Taye Gari and Alemayehu Tadesse all contributed significantly and equally to the work reported, whether in the study design, execution, acquisition of data, analysis, and interpretation, or in all of these areas; they also participated in the article's drafting, revision, and critical review; endorsed the final version for publication; and decided which journal to submit it to.\u003c/p\u003e\u003ch2\u003eAcknowledgements\u003c/h2\u003e \u003cp\u003eThe authors are grateful to the Advisors, data collectors and study participants, whose efforts and contributions made this study possible.\u003c/p\u003e\u003ch2\u003eData availability\u003c/h2\u003e \u003cp\u003eThe datasets generated and/or analysed during the current study are not publicly available [as it is the word of the participants, it may contain the privacy of an individual or maintain the privacy and confidentiality of the participants but are available from the corresponding author upon reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWHO. WHO consolidated guidelines on tuberculosis (2022) Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, update\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWHO (2024) Global tuberculosis report 2024. Geneva\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBagcchi S (2023) WHO's Global Tuberculosis Report 2022. Lancet Microbe 4(1):e20\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSidek MY, Kamarul Zaman MF, Nik Rosmawati NH, Zamzurina AB (2024) Drug-resistant tuberculosis in Malaysia: Prevalence, characteristics, and treatment outcomes. Med J Malay 79(6):661\u0026ndash;668\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIsmail N, Ismail F, Omar SV, Blows L, Gardee Y, Koornhof H et al (2018) Drug resistant tuberculosis in Africa: Current status, gaps and opportunities. Afr J Lab Med 7(2):781\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbdulkerim BMS, Mathewos A et al (2022) Determinants of Multidrug-Resistant Mycobacterium tuberculosis Infection: A Multicenter Study from Southern Ethiopia. Infect Drug Resist 2022:15 3523\u0026ndash;3535\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBiru D, Woldesemayat EM (2020) Determinants of Drug-Resistant Tuberculosis in Southern Ethiopia: A Case-Control Study. Infect drug Resist 13:1823\u0026ndash;1829\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHatiya M, Merid Y, Mola A, Belayneh F, Ali MM (2025) Prevalence of drug-resistant Mycobacterium tuberculosis and its associated factors among tuberculosis patients attending Dilla university referral hospital, Ethiopia. BMC Infect Dis 25(1):797\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWolde Z, Tadesse T, Tadesse T, Biru A, Abebe W (2020) Land size and landlessness as connotations for food security in rural low-income farmers: A case of Gedeo Zone, Southern Ethiopia. J Agricultural Sci Pract 5(1):36\u0026ndash;45\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D, Amare M et al (2018) Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLoS ONE 13(6):e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSileshi MLD, Solomon B (2021) Determinants of multi drug resistant tuberculosis among tuberculosis patients in southwest Ethiopia: Unmatched case control study\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e(FANTA) (2016) FaNTAIP. Nutrition Assessment, Counseling, and Support (NACS): A User\u0026rsquo;s Guide\u0026mdash;Module 2: Nutrition Assessment and Classification, Version 2. FHI 360/FANTA, Washington, DC\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen G, Xu K, Sun F, Sun Y, Kong Z, Fang B (2020) Risk Factors of Multidrug-Resistant Bacteria in Lower Respiratory Tract Infections: A Systematic Review and Meta-Analysis. 2020:7268519\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWako WG, Wasie A, Wayessa Z, Fikrie A (2021) Determinants of health system diagnostic delay of pulmonary tuberculosis in Gurage and Siltie zones, South Ethiopia: a cross-sectional study. BMJ open. ;11(10)\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeresa D, Berhe G, Tadesse K, Gebru M, Gebrezgabiher G (2025) Assessing the determinants of drug-resistant tuberculosis in selected hospitals in Tigray region, Northern Ethiopia: a case-control study. J Health Popul Nutr 44(1):267\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFikre ATT, Shaweno T (2019) Determinants of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients in Southern Ethiopia: A Case Control Study. J Med Bacterio 8(1, 2):1\u0026ndash;12\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZereabruk K, Kahsay TTH et al (2024) Determinants of multidrugresistant tuberculosis among adults undergoing treatment for tuberculosis in Tigray Region, Ethiopia: a case-control study. BMJ Open Respir Res\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoel S, Thakur D, Singh A (2021) Determinants of drug resistant \u0026amp; drug sensitive tuberculosis patients from North India-a case control study. Indian J Tuberc 68S:S108\u0026ndash;S14\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOumer N, Atnafu DD, Worku GT, Tsehay AK (2021) Determinants of Multi-drug resistant Tuberculosis in four treatment centers of Eastern Amhara, Ethiopia: A case-control study. J Infect developing Ctries 15(5):687\u0026ndash;695\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuluneh AA, Kassa ZY, Siyoum M, Gebretsadik A, Woldeyes Y, Tenaw Z (2020) Determinants of Sub-Optimal Birth Spacing in Gedeo Zone, South Ethiopia: A Case\u0026ndash;Control Study. Int J Women's Health 12(null):549\u0026ndash;556\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKodama Y (2007) New role of cooperatives in Ethiopia: the case of Ethiopian coffee farmers cooperatives. Afr Study Monogr. ;35\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFranke MA, Emmrich JV, Ranjaharinony F, Ravololohanitra OG, Andriamasy HE, Knauss S et al (2024) A cross-sectional analysis of the effectiveness of a nutritional support programme for people with tuberculosis in Southern Madagascar. 13(1):13\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNyamagoud SB, Dsouza PD, Chitralu SPP, Solankure K, Swamy AHV (2025) Impact of patient counseling on medication adherence and drug resistance patterns in tuberculosis patients\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ekalu TY, Clements ACA, Xu Z, Bai L, Alene KA (2024) Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study. BMC Infect Dis 24(1):198\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTsige KEG (2020) Risk factors for multi Drug_Resistant Tuberculosis among newly diagnosed MDR-TB patients of all Africa leprosy, Tuberculosis and rehabilitation training center. Alert) Hospitals, Addis Ababa, Ethiopia\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYing X, Wei Z, Ruijuan Q, Junhong (2022) Tang. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS ONE\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDemelash A, Berhanu S (2020) Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia. Infect Drug Resist 2017:10 209\u0026ndash;213\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Hawassa University","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Drug resistance, Tuberculosis, Healthcare facility, Gedeo Zone","lastPublishedDoi":"10.21203/rs.3.rs-8915478/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8915478/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eIntroduction:\u003c/strong\u003e Drug-resistant tuberculosis (DR-TB) is a form of tuberculosis caused by \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e strains that do not respond to standard anti-TB drugs. Ethiopia ranked among the top 30 countries burdened by DR-TB in the world. Although drug-resistant tuberculosis is a growing public health concern in the Gedeo Zone, determinants of DR-TB are still inadequately explored, as few studies have been undertaken in this area. Therefore, this study aimed to assess the determinants of drug-resistant tuberculosis among TB patients receivingtreatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eObjectives\u003c/strong\u003e: To assess the determinants of drug-resistant tuberculosis among TB patients receiving treatment in Gedeo Zone public healthcare facilities, southern Ethiopia, 2025\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: An institution-based unmatched case‒control study was conducted from July 21--August 19, 2025, with a total of 177 participants (59 cases and 118 controls) who attended public healthcare facilities in the Gedeo zone. A simple random sampling technique was used to select a study participant. The data were collected with the Kobo Toolbox and then exported to SPSS version 27 for analysis. Associations between dependent and independent variables were assessed via binary logistic regression. At the 95% CI, in bivariable analysis, a p value of \u0026lt;0.25 was used to select candidate variables for multivariable analysis. In the multivariable analysis, a p value of less than 0.05 was considered statistically significant.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResult:\u003c/strong\u003e In this study, 177 participants (59 cases and 118 controls) were enrolled, resulting in a 100% response rate. This study revealed that five factors were significantly associated with DR-TB in this study area: lack of formal education (AOR = 3.37, 95% CI: 1.09–10.42), urban residence (AOR = 2.54, 95% CI: 1.07–6.03), previous TB treatment history (AOR = 3.34, 95% CI: 1.57–7.09), counselling on DR-TB (AOR = 0.28, 95% CI: 0.10–0.78), and social stigma (AOR = 3.27, 95% CI: 1.56–6.84).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e Lack of formal education, urban residence, previous TB treatment history, counselling and social stigma was found to be determinants of DR-TB. Effective DR-TB control interventions focused on the above determinants need to be implemented.\u003c/p\u003e","manuscriptTitle":"Determinants of Drug Resistant Tuberculosis Among Tuberculosis Patients on Treatment in Gedeo Zone Public Healthcare Facilities, Southern Ethiopia, 2025. Unmatched case‒control study.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-20 01:01:33","doi":"10.21203/rs.3.rs-8915478/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f30db356-63ed-4731-89ed-8ea7edc19c80","owner":[],"postedDate":"February 20th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":63184597,"name":"Infectious Diseases"}],"tags":[],"updatedAt":"2026-02-20T01:01:33+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-20 01:01:33","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8915478","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8915478","identity":"rs-8915478","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}